Real world efficacy of omalizumab in reducing surgical intervention for nasal polyps in Samter’s triad
DOI:
https://doi.org/10.18203/issn.2454-2156.IntJSciRep20250062Keywords:
Real world, Samter’s triad, Nasal polypsAbstract
The advancements in the field of medicine, particularly in the field of drug application, has told us that Omalizumab has a significant impact on the management of nasal polyps, especially in the context of Samter’s triad. Our letter highlights the role of omalizumab in reducing the surgical interventions for nasal polyps which has been a longstanding challenge in the population in the past.
Metrics
References
Gevaert P, Omachi TA, Corren J, Mullol J, Han J, Lee SE, et al. Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials. J Allergy Clin Immunol. 2020;146(3):595-605. DOI: https://doi.org/10.1016/j.jaci.2020.05.032
Gevaert P, Calus L, Van Zele T, Blomme K, De Ruyck N, Bauters W, et al. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J Allergy Clin Immunol. 2013;131(1):110-6. DOI: https://doi.org/10.1016/j.jaci.2012.07.047
Damask C, Chen M, Holweg CTJ, Yoo B, Millette LA, Franzese C. Defining the Efficacy of Omalizumab in Nasal Polyposis: A POLYP 1 and POLYP 2 Subgroup Analysis. Am J Rhinol Allergy. 2022;36(1):135-41. DOI: https://doi.org/10.1177/19458924211030486
Bachert C, Zhang N, Hellings PW, Bousquet J. Endotype-driven care pathways in patients with chronic rhinosinusitis. J Allergy Clin Immunol. 2018;141(5):1543-51. DOI: https://doi.org/10.1016/j.jaci.2018.03.004
Ren L, Zhang N, Zhang L, Bachert C. Biologics for the treatment of chronic rhinosinusitis with nasal polyps - state of the art. World Allergy Organ J. 2019;12(8):100050. DOI: https://doi.org/10.1016/j.waojou.2019.100050